Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039468 | 1.00 | ACE (0.47) | ACEALDH1A1PHGDHRECQLKMT2A | |
| SCHEMBL16635521 | 1.00 | ACE (0.47) | ACEALDH1A1PHGDHRECQLKMT2A | |
| SCHEMBL3832250 | 1.00 | ACE (0.47) | ACEALDH1A1PHGDHRECQLKMT2A | |
| SCHEMBL20399837 | 1.00 | ACE (0.47) | ACEALDH1A1PHGDHRECQLKMT2A | |
| SCHEMBL15389898 | 1.00 | ACE (0.47) | ACEALDH1A1PHGDHRECQLKMT2A | |
| SCHEMBL17979188 | 0.87 | ACE (0.62) | ACEALDH1A1RECQLKMT2AGLA | |
| SCHEMBL19083695 | 0.84 | ACE (0.46) | ACEALDH1A1PHGDHRECQLKMT2A | |
| SCHEMBL19083697 | 0.84 | ACE (0.46) | ACEALDH1A1PHGDHRECQLKMT2A | |
| SCHEMBL4759483 | 0.83 | ACE (0.37) | ACEALDH1A1ATM | |
| SCHEMBL4498432 | 0.83 | PHGDH (0.44) | ACEALDH1A1PHGDHRECQLGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117460734-A | Pentacyclic derivatives as Zika virus inhibitors | 吉利德科学公司 | 2024-01-26 | — | — | CN | disclosed |
| US-8779156-B2 | Analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2550267-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BLVRB, RRP1B, C1QBP | ACE 207/4885ALDH1A1 2142/4885PHGDH 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.